English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aim  To evaluate, using  post hoc  analyses, whether the novel combination of a basal insulin, insulin degludec, and a glucagon‐like peptide‐1 receptor agonist, liraglutide ( IDegLira ), was consistently effective in patients with type 2 diabetes ( T2D ), regardless of the stage of  T2D  progression.    Methods  Using data from the  DUAL I  extension [insulin‐naïve patients uncontrolled on oral antidiabetic drugs ( OADs ), n = 1660, 52 weeks] and  DUAL II  (patients uncontrolled on basal insulin plus  OADs , n = 398, 26 weeks) randomized trials, the efficacy of  IDegLira  was investigated with regard to measures of disease progression stage including baseline glycated haemoglobin ( HbA1c ), disease duration and previous insulin dose.    Results  Across four categories of baseline  HbA1c  (≤7.5–9.0%),  HbA1c  reductions were significantly greater with  IDegLira  (1.1–2.5%) compared with  IDeg  or liraglutide alone in  DUAL I . In  DUAL II ,  HbA1c  reductions were significantly greater with  IDegLira  (0.9–2.5%) than with  IDeg  in all but the lowest  HbA1c  category. In  DUAL I , insulin dose and hypoglycaemia rate were lower across all baseline  HbA1c  categories for  IDegLira  versus  IDeg , while hypoglycaemia was higher with  IDegLira  than liraglutide, irrespective of baseline  HbA1c . In  DUAL II , insulin dose and hypoglycaemia rate were similar with  IDegLira  and  IDeg  (maximum dose limited to 50 U) independent of baseline  HbA1c . The reduction in  HbA1c  with  IDegLira  was independent of disease duration and previous insulin dose but varied depending on pre‐trial  OAD  treatment.    Conclusions   IDegLira  effectively lowered  HbA1c  across a range of measures, implying suitability for patients with either early or advanced  T2D .

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes